PROSpect's phase 3 RCT enrolled 424 children with PARDS and found neither prone positioning nor HFOV improves ventilator-free ...
CluePoints positions RBQM architecture as the structural foundation for clinical monitoring, consolidating evidence across ...
The PROSpect trial found neither prone positioning nor HFOV improved ventilator-free days in PARDS, and the trial design that ...
PharPoint Research joins Medrio's Early Adopter Program to shape clinical trial management system design before product ...
Moleculin Biotech completes dosing in Phase 2/3 MIRACLE trial for AnnAraC in relapsed/refractory AML, with full data expected ...
Zhimeng Biopharma completes enrollment of CB03-154 Phase 2/3 ALS trial with 255 patients across China, targeting Q3 2027 ...
AnnJi Pharmaceutical has filed its Phase 3 protocol with the FDA and is moving to activate U.S. sites for ROMA-KD, a global, randomized, double-blind, placebo-controlled trial targeting roughly 200 ...
Lundbeck’s Phase III MASCOT trial enrolled 401 participants with clinically probable or established multiple system atrophy, and the first public look at that population lands this week as a ...
The central design problem in all-in-one diabetes patches is whether a glucose sensor placed next to an insulin delivery site can still read accurately right after a bolus. Data from the SMART02 ...
SpyGlass Pharma's Bimatoprost Pad-IOL demonstrates four-year durability in first-in-human trial, supporting two ongoing Phase ...
FL-020 achieves 88% PSA50 response in Phase 1 mCRPC study, including benefit in patients previously treated with lutetium-177.
RAP-219 hits primary endpoint in Phase 2 bipolar mania trial with statistically significant 3.1-point placebo-adjusted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results